军事知识服务平台
同步加量调强放疗联合尼妥珠单抗治疗局部晚期食管癌
Short-term efficacy and toxicity of Nimotuzumab combined with simultaneous integrated boost intensity-modulated radiotherapy for locally advanced esophageal cancer
摘要 目的 评价同步加量调强放疗(SIB-IMRT)联合尼妥珠单抗(泰欣生,h-R3)治疗局部晚期食管癌的近期疗效及安全性.方法 29例原发食管癌患者均采用同步加量调强放疗技术,处方剂量:PGTV/PGTVnd 60 Gy/2.4 Gy/25 F、PTV 50 Gy/2 Gy/25 F,每周泰欣生200 mg靶向治疗,同时观察近期疗效及急性不良反应.结果 29例患者均完成既定治疗方案,其中CR 14例(48.3%)、PR 13例(44.8%)、SD 1例(3.6%)、PD 1例(3.6%),有效率为93.1%.主要不良反应为Ⅰ~Ⅱ度放射性食管炎、骨髓抑制及放射性皮炎;尼妥珠单抗不良反应轻微,仅1例患者出现轻微皮疹.结论 同步加量调强放疗联合尼妥珠单抗治疗食管癌近期疗效较好,患者治疗耐受性良好,值得临床进一步研究.
Abstract:
Objective To evaluate the short-term efficacy and toxicity of Nimotuzumab combined with simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) in the treatment of locally advanced esophageal carcinoma.Methods Twenty-nine patients with esophageal carcinoma were treated with SIB-IMRT.Planning gross target volume (PGTV) was given at a dose of 60 Gy/2.4 Gy/25 F and planning target volume (PTV) was given at a dose of 50 Gy/2 Gy/25 F.Nimotuzumab was given by intravenous drip at the dose of 200 mg,once a week before radiotherapy.Short-term efficacy and toxicity were evaluated in all patients.Results All patients completed the treatment successfully.Fourteen of them achieved a complete response (CR,48.3%),13 had a partial response (PR,44.8%),1 showed stable disease (SD,3.6%),and 1 showed progressive disease (PD,3.6%).The overall response rate (CR + PR) was 93.1%.Most adverse reactions were radioactive esophagitis,radioactive dermatitis and bone marrow suppression (grade 1-2).Only 1 patient developed a slight skin rash.Conclusion Nimotuzumab combined with SIB-IMRT is a safe and effective modality for locally advanced esophageal cancer.The patient is well tolerated and worthy of further clinical study.
Author: Chen Zhiming Xue Qiang Chen Xiaojue Shi Jian Ma Jianbo Ji Bin Chen Buyou
作者单位: 南通大学附属医院肿瘤放疗科, 江苏,226001
刊 名 中华医学杂志 ISTICPKU
年,卷(期): 2016, 96(8)
机标分类号: R730.55 R473.73 R273
在线出版日期: 2016年3月31日